TRUE-SHF shakes up beliefs about treating acute decompensated heart failure
from Medscape (free login required)
Early intravenous treatment with a synthetic natriuretic peptide decongested patients with acute decompensated heart failure (ADHF) and made them feel better in the first 48 hours but did nothing to improve long-term survival, in a large randomized trial. Nor did the drug, ularitide (Cardiorentis), an analogue of native urodilatin, seem to protect the myocardium from damage as measured by troponin levels, which was an important prospective end point in the Trial of Ularitide Efficacy and Safety in Acute Heart Failure (TRUE-AHF).
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063